FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2332364317> ?p ?o ?g. }

• W2332364317 endingPage "32542" @default.
• W2332364317 startingPage "32532" @default.
• W2332364317 abstract "// Norbert Vey 1, 2 , Jacques Delaunay 3 , Giovanni Martinelli 4 , Walter Fiedler 5 , Emmanuel Raffoux 6 , Thomas Prebet 1 , Carlos Gomez-Roca 7, 8 , Cristina Papayannidis 4 , Maxim Kebenko 5 , Peter Paschka 9 , Randolph Christen 10 , Ernesto Guarin 11 , Ann-Marie Bröske 12 , Monika Baehner 12 , Michael Brewster 13 , Antje-Christine Walz 11 , Francesca Michielin 11 , Valeria Runza 12 , Valerie Meresse 11 , Christian Recher 7, 14 1 Institut Paoli-Calmettes, Marseille, France 2 Aix Marseille Université, Marseille, France 3 Service d'Hématologie Clinique, Hôpital Hôtel-Dieu, Nantes, France 4 Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy 5 Department of Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 6 Hôpital Saint Louis, AP-HP, EA3518 Université Paris VII, Paris, France 7 Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France 8 Institut Claudius Regaud, Clinical Research Unit, Toulouse, France 9 Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany 10 Product Development, Safety Risk Management, Roche, Basel, Switzerland 11 Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland 12 Pharma Research & Early Development, Roche Innovation Center Penzberg, Penzberg, Germany 13 Pharma Research & Early Development, Roche Innovation Centre, Welwyn, UK 14 CHU de Toulouse, Université Toulouse III, Toulouse, France Correspondence to: Norbert Vey, email: veyn@ipc.unicancer.fr Keywords: RG7356, relapsed/refractory acute myeloid leukemia, anti-CD44 humanized antibody, phase I trial, cell adhesion Received: January 20, 2016      Accepted: March 28, 2016      Published: April 11, 2016 ABSTRACT RG7356, a recombinant anti-CD44 immunoglobulin G1 humanized monoclonal antibody, inhibits cell adhesion and has been associated with macrophage activation in preclinical models. We report results of a phase I dose-escalation study of RG7356 in relapsed/refractory acute myeloid leukemia (AML). Eligible patients with refractory AML, relapsed AML after induction chemotherapy, or previously untreated AML not eligible for intensive chemotherapy were enrolled and received intravenous RG7356 at dosages ≤ 2400 mg every other week or ≤ 1200 mg weekly or twice weekly; dose escalation started at 300 mg. Forty-four patients (median age, 69 years) were enrolled. One dose-limiting toxicity occurred (grade 3 hemolysis exacerbation) after one 1200 mg dose (twice-weekly cohort). The majority of adverse events were mild/moderate. Infusion-related reactions occurred in 64% of patients mainly during cycle 1. Two patients experienced grade 3 drug-induced aseptic meningitis. Pharmacokinetics increased supraproportionally, suggesting a target-mediated drug disposition (TMDD) at ≥ 1200 mg. Two patients achieved complete response with incomplete platelet recovery or partial response, respectively. One patient had stable disease with hematologic improvement. RG7356 was generally safe and well tolerated. Maximum tolerated dose was not reached, but saturation of TMDD was achieved. The recommended dose for future AML evaluations is 2400 mg every other week." @default.
• W2332364317 created "2016-06-24" @default.
• W2332364317 creator A5002046745 @default.
• W2332364317 creator A5010990164 @default.
• W2332364317 creator A5015827960 @default.
• W2332364317 creator A5028244645 @default.
• W2332364317 creator A5033422703 @default.
• W2332364317 creator A5035222674 @default.
• W2332364317 creator A5037583023 @default.
• W2332364317 creator A5044624520 @default.
• W2332364317 creator A5047145227 @default.
• W2332364317 creator A5053724616 @default.
• W2332364317 creator A5059503499 @default.
• W2332364317 creator A5064103067 @default.
• W2332364317 creator A5066708720 @default.
• W2332364317 creator A5068730563 @default.
• W2332364317 creator A5073761054 @default.
• W2332364317 creator A5078439299 @default.
• W2332364317 creator A5081322213 @default.
• W2332364317 creator A5081614049 @default.
• W2332364317 creator A5084039929 @default.
• W2332364317 creator A5091508845 @default.
• W2332364317 date "2016-04-11" @default.
• W2332364317 modified "2023-10-03" @default.
• W2332364317 title "Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia" @default.
• W2332364317 cites W147516046 @default.
• W2332364317 cites W1538746713 @default.
• W2332364317 cites W1910470233 @default.
• W2332364317 cites W1979421565 @default.
• W2332364317 cites W1987570598 @default.
• W2332364317 cites W1988785438 @default.
• W2332364317 cites W1989479024 @default.
• W2332364317 cites W1990564763 @default.
• W2332364317 cites W2006445674 @default.
• W2332364317 cites W2025491043 @default.
• W2332364317 cites W2037632318 @default.
• W2332364317 cites W2042486830 @default.
• W2332364317 cites W2050471721 @default.
• W2332364317 cites W2053413169 @default.
• W2332364317 cites W2058155210 @default.
• W2332364317 cites W2061573227 @default.
• W2332364317 cites W2062069198 @default.
• W2332364317 cites W2065741000 @default.
• W2332364317 cites W2079113620 @default.
• W2332364317 cites W2097035477 @default.
• W2332364317 cites W2097126393 @default.
• W2332364317 cites W2097192169 @default.
• W2332364317 cites W2098334197 @default.
• W2332364317 cites W2102304044 @default.
• W2332364317 cites W2113753666 @default.
• W2332364317 cites W2115675689 @default.
• W2332364317 cites W2116858301 @default.
• W2332364317 cites W2129510594 @default.
• W2332364317 cites W2137605834 @default.
• W2332364317 cites W2149110214 @default.
• W2332364317 cites W2158022600 @default.
• W2332364317 cites W2158240777 @default.
• W2332364317 cites W2159507916 @default.
• W2332364317 cites W2468105544 @default.
• W2332364317 cites W4297754244 @default.
• W2332364317 cites W4376595466 @default.
• W2332364317 doi "https://doi.org/10.18632/oncotarget.8687" @default.
• W2332364317 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5078031" @default.
• W2332364317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27081038" @default.
• W2332364317 hasPublicationYear "2016" @default.
• W2332364317 type Work @default.
• W2332364317 sameAs 2332364317 @default.
• W2332364317 citedByCount "71" @default.
• W2332364317 countsByYear W23323643172016 @default.
• W2332364317 countsByYear W23323643172017 @default.
• W2332364317 countsByYear W23323643172018 @default.
• W2332364317 countsByYear W23323643172019 @default.
• W2332364317 countsByYear W23323643172020 @default.
• W2332364317 countsByYear W23323643172021 @default.
• W2332364317 countsByYear W23323643172022 @default.
• W2332364317 countsByYear W23323643172023 @default.
• W2332364317 crossrefType "journal-article" @default.
• W2332364317 hasAuthorship W2332364317A5002046745 @default.
• W2332364317 hasAuthorship W2332364317A5010990164 @default.
• W2332364317 hasAuthorship W2332364317A5015827960 @default.
• W2332364317 hasAuthorship W2332364317A5028244645 @default.
• W2332364317 hasAuthorship W2332364317A5033422703 @default.
• W2332364317 hasAuthorship W2332364317A5035222674 @default.
• W2332364317 hasAuthorship W2332364317A5037583023 @default.
• W2332364317 hasAuthorship W2332364317A5044624520 @default.
• W2332364317 hasAuthorship W2332364317A5047145227 @default.
• W2332364317 hasAuthorship W2332364317A5053724616 @default.
• W2332364317 hasAuthorship W2332364317A5059503499 @default.
• W2332364317 hasAuthorship W2332364317A5064103067 @default.
• W2332364317 hasAuthorship W2332364317A5066708720 @default.
• W2332364317 hasAuthorship W2332364317A5068730563 @default.
• W2332364317 hasAuthorship W2332364317A5073761054 @default.
• W2332364317 hasAuthorship W2332364317A5078439299 @default.
• W2332364317 hasAuthorship W2332364317A5081322213 @default.
• W2332364317 hasAuthorship W2332364317A5081614049 @default.
• W2332364317 hasAuthorship W2332364317A5084039929 @default.
• W2332364317 hasAuthorship W2332364317A5091508845 @default.
• W2332364317 hasBestOaLocation W23323643171 @default.

• next